Common Single Nucleotide Polymorphisms in Genes Related to Immune Function and Risk of Papillary Thyroid Cancer

Alina V. Brenner1, Gila Neta1, Erich M. Sturgis2, Ruth M. Pfeiffer3, Amy Hutchinson4, Meredith Yeager4, Li Xu2, Cindy Zhou5, William Wheeler6, Margaret A. Tucker7, Stephen J. Chanock8, Alice J. Sigurdson1

Introduction

Thyroid carcinoma is the most common endocrine malignancy and its incidence has increased worldwide during the last 40 years [1–3]. Although improved diagnosis and reporting have likely contributed to this trend, additional reasons remain unclear [3]. Thyroid cancer is consistently more common in females, with a female-to-male ratio in incidence rates of about 3 to 1 [4]. One of the best established etiologic factors for thyroid carcinoma and its most common histologic type, papillary thyroid cancer (PTC), is exposure to ionizing radiation during childhood [5,6]. Family history studies suggest that thyroid cancer may have a greater familial component than other cancers with relative risk (RR) estimates of 3–4 or higher for a family history in first-degree relatives [7,8]. Recent genome-wide association studies (GWAS) [9,10] and a candidate gene study [11] have clearly implicated the SERPINA5 gene, which codes for the protein C inhibitor SERPINA5 gene, which codes for the protein C inhibitor.

Citation: Brenner AV, Neta G, Sturgis EM, Pfeiffer RM, Hutchinson A, et al. (2013) Common Single Nucleotide Polymorphisms in Genes Related to Immune Function and Risk of Papillary Thyroid Cancer. PLoS ONE 8(3): e57243. doi:10.1371/journal.pone.0057243

Editor: Xiao-Ping Miao, Huazhong University of Science and Technology, China

Received August 7, 2012; Accepted January 18, 2013; Published March 8, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This project was supported in part by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, by federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E, and by a grant from the American Thyroid Association (PI: E. M. Sturgis). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have the following interests: co-authors AH and MY are employed by Core Genotyping Facility, SAIC-Frederick Inc. Co-author WW is employed by Information Management Systems (IMS), Silver Spring, Maryland. There are no patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.

* E-mail: brennera@mail.nih.gov
Apart from childhood exposure to radiation and genetic predisposition, accumulating epidemiological, histological, and molecular evidence suggests that alterations in immune function might be related to risk of PTC [12,13]. Chronic inflammation increasingly has been associated with many cancer types including PTC [12–14]. While the exact mechanism for these associations is unclear, it has been hypothesized that persistent inflammation leads to increased cellular turnover and provides selection pressure resulting in the emergence of cells that are at high risk for malignant transformation [14]. A history of autoimmune disease, in which inappropriate immune activation results in tissue destruction and inflammation, has also been associated with increased risk of PTC [15]. The most consistent associations for PTC are reported with a history of chronic autoimmune thyroiditis or Hashimoto thyroiditis (HT) [16,17], both more common in females [4,18]. At a histological level, HT and PTC share lymphoid infiltration, expression of galectin 3, CITED1, cytokeratin 19, and fibronectin 1 through which the association might be mediated [12,16]. At the molecular level, activation of proinflammatory MAPK-signaling pathway through RET/PTC rearrangement might contribute to development of HT-associated PTC [12,17]. Recently common germline polymorphisms in immune-related genes have been associated with risk of many autoimmune diseases, including HT [19,20], but such data in relation to PTC are sparse.

Given emerging relationships between immune dysfunction and PTC, we sought to identify genetic susceptibility markers for PTC in a case-control study of 344 PTC cases and 452 controls by evaluating 3,985 tag single nucleotide polymorphisms (SNPs) in 230 candidate gene regions involved in various immune pathways (adhesion-extravasation-migration, arachidonic acid metabolism/ eicosanoid signaling, complement and coagulation cascade, cytokine signaling, innate pathogen detection and antimicrobials, leukocyte signaling, TNF/NF-kB signaling and other). This effort extends previous candidate gene based studies of PTC by increasing the number and coverage of promising genes implicated in the development of inflammation, autoimmunity, and carcinoma-genesis.

Materials and Methods

Study Population

Cases included thyroid cancers (n = 202) diagnosed within the U.S. Radiologic Technologists (USRT) cohort as described previously [21] and cancers (n = 142) diagnosed and treated at the University of Texas M.D. Anderson Cancer Center (UTMDACC) [22]. All cases were histologically confirmed. Controls (n = 452) were selected from the USRT study [23] and frequency-matched to the USRT cases by sex and year of birth (+/−2 years). These controls were also used for the combined case series (USRT and UTMDACC). Both studies were reviewed and approved by the Special Studies Institutional Review Board of the National Cancer Institute and Institution Review Board of the University of Texas M.D. Anderson Cancer Center, respectively. All subjects provided written informed consent.

To minimize the potential for population stratification and phenotypic heterogeneity of thyroid cancer cases, we excluded individuals with non-European ancestry (n = 97) and cases with follicular thyroid cancer (n = 17) leaving 344 papillary thyroid cancer cases (n = 202 USRT and n = 142 UTMDACC) and 452 controls of European ancestry with validated genotyping results. Allele frequencies for papillary thyroid cancer cases of European ancestry were largely similar between the USRT and the UTMDACC study sites and between males and females, so these groups were combined for genetic analyses.

Variable Collection and Data Harmonization

Data concerning demographics, health history, family history of cancer, and other risk factors were collected by self-administered mailed questionnaires or telephone interview in the USRT study or a self-administered questionnaire at the time of blood collection in the UTMDACC study. Race, histological type of thyroid cancer, and history of autoimmune thyroiditis were defined similarly in both studies. Other variables were harmonized across the two studies (cigarette smoking, alcohol consumption, prior exposure to therapeutic radiation, and family history of any cancer or specifically of thyroid cancer). Because controls were matched to cases on year of birth (+/−2 years), and to enable time-appropriate partitioning of exposures (such as cigarette smoking), we assigned a referent age to controls to correspond to the time of a case’s diagnosis. Specifically, a control for a particular case was randomly selected from case-defined strata of sex and year of birth. If no control could be found then matching on sex and year of birth was relaxed (in that order). The algorithm was repeated until referent age was assigned to every control. Time dependent exposures in controls were accounted for up to the referent age and ignored thereafter.

Laboratory Methods

DNA extraction. In the USRT study, venipuncture whole blood samples were shipped with a temperature stabilizing pack overnight to the processing laboratory in Frederick, MD. At UTMDACC, venipuncture whole blood samples were collected and processed in the clinic. Both studies extracted DNA from peripheral blood leucocytes using Qiagen Mini Kits (Qiagen Inc., Valencia, CA) according to the manufacturer’s instructions.

Genotyping. Genotyping of 27,904 SNPs, including tag SNPs in 1,316 candidate genes and their surrounding regions (within 20 kb 5’ of the start of transcription at the first exon and 10 kb 3’ of the last exon) and intergenic SNPs included on the platform because of associations with several cancers, was performed at the NCI Core Genotyping Facility (Advanced Technology Center, Gaithersburg, MD; http://cgf.nci.nih.gov/) using the custom-designed iSelect Infinium assay (Illumina, www. illumina.com). Tag SNPs were selected for target gene regions from the common SNPs (minor allele frequency, MAF >5%) genotyped by the HapMap Project (Data Release 20/Phase II, NCBI Build 36.1, assembly dbSNPb126) in the Caucasian population (CEU) using TagZilla software (http://tagzilla.ncbi.nlm.nih.gov/) based on the pairwise binning method of Carlson et al. [24] with a binning threshold of $r^2$>0.8.

Quality control. Out of 27,904 SNPs included in the genotyping platform, 722 failed genotyping (no amplification or clustering) and 208 had monomorphic calls and were excluded from the analysis. SNPs with <95% concordance (n = 656) or <90% completion (n = 740) among randomly inserted quality control replicates, and 740 SNPs that failed the Hardy-Weinberg Equilibrium test in controls (P value <0.00001) were also excluded. Of the 947 study participants with DNA specimens (n = 232 USRT cases, n = 223 UTMDACC cases, n = 492 USRT controls), we excluded subjects if their samples failed genotyping (n = 18), were not assayed (n = 4), or had less than 90% completion rate (n = 15).
Polymorphisms in Immunity Genes and Thyroid Cancer

Final Set of Tag SNPs, Sub-pathways, and Analytic Population

Following quality control related exclusions, we also excluded in the analysis 1,607 intergenic SNPs that had been previously implicated in etiology of non-thyroid cancers, and 5,706 tag SNPs with the MAF <10% or the lowest achievable significance level computed from the marginal totals >1-30 [25]. After all exclusions, there were 17,525 tag SNPs in 1,129 gene regions available for analysis. Of these, 3,985 SNPs were in 230 gene regions involved in immune-related pathways that are the subject of the current analysis. The candidate gene regions were further subdivided into eight a priori defined pathways (adhesion-extravasation-migration, arachidonic acid metabolism/eicosanoid signaling, complement and coagulation cascade, cytokine signaling, innate pathogen detection and antimicrobials, leukocyte signaling, TNF/NF-kB signaling, and other) largely based on classifications from Loza et. al. [26]. When assigning gene regions with a broad range of known functions, we allowed for allocation to multiple pathways. A complete list of the 230 gene regions and their allocation to the respective pathways is available in Table S1.

Statistical Analysis

We organized the analytic approach by first examining the relationship of individual SNPs with PTC risk, followed by examining relationships at the gene region level, pathway level, and overall to also detect small SNP effects that could only be detected in the aggregate.

SNP-based associations. Logistic regression models were used to estimate odds ratios (ORs) and to calculate 95% confidence intervals (CIs) of the association of PTC risk with each SNP genotype, coded as 0, 1, 2, with 0 through 2 denoting the number of minor alleles. We calculated the linear $P_{SNP\_trend}$ for SNP genotype in crude models and models adjusted for sex, attained age in four categories (<35, 35–44, 45–54, 55+ years), and year of birth (<1940, 1940–1949, 1950+) as an ordinal variable. The ORs from models with and without adjustments were very similar, so we present the results from the adjusted models. For the top SNPs ($P_{SNP\_trend} <0.001$), we repeated analyses of main effects while also (1) adjusting for history of autoimmune thyroiditis, (2) limiting to individuals without autoimmune thyroiditis, and (3) limiting to females. For the top SNPs we also conducted interaction analyses with attained age and history of autoimmune thyroiditis. These analyses were based on one degree of freedom likelihood ratio tests comparing the fit of two models: (1) including main effect of genotype (0, 1, 2) and continuous age or history of autoimmune thyroiditis (0, 1), and (2) including also the multiplicative interaction term between the genotype and age or autoimmune thyroiditis. To correct for multiple comparisons, we used the false discovery rate (FDR) control method [27].

Gene region- and pathway-based analyses. We combined SNP specific $P$ values of linear trend within the same gene region ($P_{Region}$) using an adaptive rank truncated product (ARTP) method [28]. This method accounts for the linkage disequilibrium (LD) structure within the gene region and accounts for the number of SNPs included in the $P$ value calculation. For the subset of genes with $P_{Region} <0.01$, we evaluated pairwise indices of LD ($D'$ and $r^2$) in controls using the Haploview package [29]. Gene region-level $P$ values were further combined into the $P$ values for pathways ($P_{Pathway}$) and an overall $P$ value for the entire group of immune genes ($P_{Overall}$) using the ARTP method. Pathway-based analyses were repeated including and excluding gene regions with multiple allocations.

Statistical analyses were conducted in SAS version 9.1 (SAS Institute, Cary, NC) and in R, unless otherwise noted.

Results

The characteristics of 344 PTC cases and 452 controls are summarized in Table 1. There was a lower proportion of females among cases compared to controls (79.7% vs. 93.6%) owing to the fact that study controls were originally selected from the USRT cohort to match the USRT cases (90.6% female), but subsequently were used for the UTMDACC cases containing a lower proportion of females (64.1%). The distribution of referent age in cases and controls was comparable. After controlling for sex and age, cases were less likely to smoke ($P<0.001$) or to have several family members with a history of cancer ($P=0.009$). Cases were also less likely than controls to drink alcohol, although this difference was not statistically significant ($P=0.073$), but more likely to have at least one family member with a history of thyroid cancer ($P=0.006$), a higher body mass index ($P<0.001$), and a personal history of autoimmune thyroiditis ($P<0.001$). The adjusted OR associated with a history of autoimmune thyroiditis was 6.4 (95% CI: 3.0–13.4).

SNP-based Associations

While the observed distribution of $P$ values of linear trend for all 3,985 SNPs was not statistically different from the expected uniform (null) distribution, there was some suggestion of departure from the null in the area of lowest $P$ values (Figure 1). Seven SNPs in four gene regions were associated with risk of PTC at $P_{SNP\_trend} <0.001$ (Table 2; a complete list of all $P_{SNP\_trend}$ values is available in Table S2). Of these, four SNPs (rs6115, rs6112, rs6108, rs10139508) were in the SERPINA5 gene and the remaining SNPs were in the MASP1 (rs850316), HEMGN (rs10984462), and TICAM1 (rs2292151) genes, respectively. Two SNPs (rs6115, rs6112) remained significant after FDR correction ($P_{SNP\_FDR} =0.02$ and $P_{SNP\_FDR} =0.04$, respectively); both were in SERPINA5. The LD structure for the SERPINA5 gene is presented in Figure 2. There is evidence that the two most significant SNPs (rs6115 and rs6112) are in LD with one another ($D' =0.95$ and $r^2 =0.47$). The associations with the top SNPs were not meaningfully changed when analyses were adjusted for history of autoimmune thyroiditis or restricted to individuals without history of autoimmune thyroiditis or conducted only among females (data not shown).

Gene Region-based Associations

Largely consistent with individual SNP analyses, four gene regions (SERPINA5, HEMGN, TICAM1, and FCGR2A) were associated with PTC risk at $P_{Region} <0.01$ (Table 3). After multiple comparisons adjustment, only SERPINA5 remained suggestively associated with PTC risk at $P_{Region\_FDR} =0.069$. All gene region-based results are available in Table S3.

Pathway-based Associations

Two immunity pathways, complement and coagulation cascade including the SERPINA5 gene and TNF/NF-kB signaling pathway including the HEMGN gene, were significantly associated with risk of PTC ($P_{Pathway} =0.02$ including and $P_{Pathway} =0.02$ excluding overlap; and $P_{Pathway} =0.05$ including and $P_{Pathway} =0.04$ excluding overlap, respectively) (Table 4). The immunity pathway as a whole was not statistically significantly associated with PTC risk.
Discussion

We evaluated the associations of 3,985 tag SNPs in 230 candidate genes from several immune pathways in relation to risk of PTC. The gene collection overall was not significantly associated with risk of PTC. In pathway-based analyses, the complement and coagulation cascade and TNF/NF-kB signaling pathway were significantly associated with risk of PTC. These findings were largely attributed to the effects of SERPINA5 and

Table 1. Characteristics of the study population by case and control status, U. S. Radiologic Technologists Study and University of Texas M. D. Anderson Cancer Center Study.

| Characteristic                                      | Cases (N = 344) | Controls (N = 452) | P a |
|---------------------------------------------------|-----------------|--------------------|-----|
| Study                                             |                 |                    |     |
| Radiologic Technologists                          | 202 (58.7)      | 452 (100.0)        |     |
| M. D. Anderson Cancer Center                      | 142 (41.3)      | 0                  |     |
| Gender                                            |                 |                    | <0.001 |
| Female                                            | 274 (79.7)      | 423 (93.6)         |     |
| Male                                              | 70 (20.3)       | 29 (6.4)           |     |
| Attained/referent age, year                       |                 |                    | 0.360 |
| 19–25                                             | 26 (7.6)        | 30 (6.6)           |     |
| 26–35                                             | 73 (21.2)       | 103 (22.8)         |     |
| 36–45                                             | 113 (32.8)      | 159 (35.2)         |     |
| 46–55                                             | 77 (22.4)       | 105 (23.2)         |     |
| 56–65                                             | 43 (12.5)       | 49 (10.8)          |     |
| 66–79                                             | 12 (3.5)        | 6 (1.3)            |     |
| Smoking status b                                  |                 |                    | <0.001 |
| Never                                             | 208 (60.5)      | 234 (51.8)         |     |
| Former                                            | 87 (25.3)       | 101 (22.4)         |     |
| Current                                           | 48 (14.0)       | 113 (25.0)         |     |
| Unknown                                           | 1 (0.3)         | 4 (0.9)            |     |
| Alcohol consumption b                             |                 |                    | 0.073 |
| Never                                             | 179 (52.0)      | 213 (47.1)         |     |
| Ever                                              | 158 (45.9)      | 221 (48.9)         |     |
| Unknown                                           | 7 (2.0)         | 18 (4.0)           |     |
| Number of relatives with cancer b                 |                 |                    | 0.009 |
| None                                              | 170 (49.4)      | 171 (37.8)         |     |
| One                                               | 107 (31.1)      | 180 (39.8)         |     |
| Two                                               | 39 (11.3)       | 64 (14.2)          |     |
| Three or more                                     | 18 (5.2)        | 33 (7.3)           |     |
| Adopted                                           | 0               | 4 (0.9)            |     |
| Unknown                                           | 10 (2.9)        | 0                  |     |
| Number of relatives with thyroid cancer b         |                 |                    | 0.006 |
| None                                              | 319 (92.7)      | 442 (97.8)         |     |
| At least one                                      | 15 (4.4)        | 6 (1.3)            |     |
| Adopted                                           | 0               | 4 (0.9)            |     |
| Unknown                                           | 10 (2.9)        | 0                  |     |
| BMI, kg/m² b                                      |                 |                    | <0.001 |
| Mean (sd)                                         | 26.1 (6.0)      | 24.4 (4.7)         |     |
| History of autoimmune thyroiditis b               |                 |                    | <0.001 |
| No                                                | 277 (80.5)      | 432 (95.6)         |     |
| Yes                                               | 48 (14.0)       | 9 (2.0)            |     |
| Unknown                                           | 19 (5.5)        | 11 (2.4)           |     |

*Test of independence.

As of referent age. See text for description of referent age assignment.

Adjusted for sex and attained age.

doi:10.1371/journal.pone.0057243.t001
HEMGN genes, respectively. At the SNP level, the strongest associations were found for two SNPs in the SERPINA5 gene (rs6115 and rs6112), both of which persisted after FDR correction and were independent of history of autoimmune thyroiditis. While our findings require replication, they strongly suggest that the SERPINA5 gene region might be a novel susceptibility locus for PTC.

The main findings in our study are internally consistent in that at the SNP, gene region, and pathway level they are attributed to the SERPINA5 gene. This gene is located on human chromosome 14 at position 14q32.1 and codes the protein C inhibitor (PCI), a member of the plasma serine protease inhibitor family [30]. While originally it was discovered as an inhibitor of activated protein C, today PCI is known to play a role in many biological processes beyond hemostasis and thrombosis including inflammation, innate immunity, carcinogenesis, and fertilization [30–33]. Recent proteomic analysis of human multiple sclerosis lesions by sensitive mass spectrometry implicated PCI in the development of chronic active plaques and suggested an unexpected intersection between coagulation and inflammation [34]. The expression of SERPINA5 was found to be significantly reduced in advanced-stage serous ovarian borderline tumors and serous carcinomas when compared with the early-stage counterparts, and such a reduction was linked to more aggressive features of the ovarian borderline tumors [35]. We were unable to find any reports of changes in SERPINA5 expression in thyroid cancer, although several studies reported over-expression in SERPINA1 (belonging to the same gene cluster on human chromosome 14q32.1) in sporadic and radiation-related thyroid cancers [36,37]. The relationship of over-expression in SERPINA1 to SERPINA5 SNPs is unclear and needs to be interpreted cautiously. To our knowledge, there have been no reports of germline polymorphisms in SERPINA5 in relation to risk of thyroid cancer or any other cancer, but there have been several reports of associations with the rate of fertilization failure [38] or risk of Wegener’s granulomatosis [39], an autoimmune vasculitis syndrome. It is intriguing that one of the two linked SNPs in SERPINA5 gene (rs6115), which withstood correction for multiple comparisons, results in a serine to asparagine amino acid change at position 64. However, whether the observed positive association between rs6115 polymorphism and risk of PTC is due to changes in PCI properties related to amino acid substitution or to potential LD with another unidentified variant remains unknown and requires further evaluation.

The second strongest association found in our study concerned SNPs in the HEMGN gene, although these did not withstand correction for multiple comparisons at the individual SNP and gene level. Interestingly, the HEMGN gene is located on chromosome 9q22.33 within a LD region including the FOXE1 gene necessary for maintenance of the differentiated state of the thyroid [40]. Several recent GWAS and a parallel candidate gene study reported consistent associations between variants in the FOXE1 region (rs965513, rs1867277, rs7850258) and risk of papillary thyroid cancer and/or primary hypothyroidism [9–11,41,42]. Unfortunately, the FOXE1 gene was not included in our genotyping platform, but due to extensive linkage in the area, signal associated with HEMGN is unlikely to be independent and is in accord with previously reported associations for variants in FOXE1.

In interpreting the results of our study, several strengths and limitations need to be considered. Because survival rates for
Figure 2. Linkage disequilibrium (LD) representation of the SERPINA5 gene. The figure represents LD based on the genotyping data from the study controls with European ancestry. LD is measured by $D'$ parameters (top panel) and the $r^2$ correlation coefficient (bottom panel). $D'$ and $r^2$ values of one are interpreted as complete LD.

doi:10.1371/journal.pone.0057243.g002
PTC are exceptionally high, any associations that might be due to survival bias are unlikely. Our study had high participation rates, minimizing potential for selection bias. To minimize concerns about population stratification, all analyses were limited to individuals of European ancestry. Moreover, cases from the two studies were similar with regard to age at diagnosis, smoking status, tumor size, and frequency of many alleles. Other strengths of our study include a thorough selection of genes related to a variety of immunity pathways. The proportion of females in the UTMDACC cases was lower than in the USRT cases and respective controls; to assure that the observed associations are not confounded, analyses were adjusted for sex. Results based on adjusted analysis as well as on analysis restricted to females were not meaningfully different. Similarly, the observed associations appeared to be independent of history of autoimmune thyroiditis. Relative to GWAS, the coverage of selected gene regions was higher, although we could have missed important associations with SNPs in gene regions not included within the genotyping platform such as in FOXE1.

While among the larger studies in the field with respect to the number of thyroid cancer cases and controls, our study had limited power (80%) to detect modest-to-weak associations (OR, 1.7) especially for less common genetic variants (MAF \#10%). Another limitation is the use of tag SNPs that are themselves unlikely to be the disease-related SNPs, but are assumed to be in LD with the causal variant. To address these limitations, we excluded SNPs with MAF \#10% and relied on robust gene/pathway ARTP methods combining SNP-specific P values of linear trend to confirm associations with risk of PTC. Although we targeted genes with strong prior evidence and adjusted for multiple comparisons using the FDR method, we cannot exclude the possibility of false positives.

In summary, we identified a promising susceptibility locus for PTC in the SERPINA5 gene belonging to the complement and coagulation cascade pathway and confirmed previously reported associations with polymorphisms in the FOXE1 - HEMGN region. Subsequent replication and fine mapping studies with adequate power would be important to validate this finding.

### Table 2. Odds ratio and 95% confidence interval (CI), adjusted for sex, attained age, and year of birth, for the tag SNPs associated with papillary thyroid cancer risk at $P_{SNP-trend} < 0.001$.

| Gene Region | SNP | Genotype | Cases | Controls | Odds Ratio | 95% CI | $P_{SNP-trend}$ | $P_{SNP-FDR}$ |
|-------------|-----|----------|-------|----------|------------|--------|----------------|---------------|
| SERPINA5    | rs6115 | AA | 119 (35.2) | 228 (51.5) | 1.00 | Referent | | |
|             |      | AG | 148 (43.8) | 161 (36.3) | 1.68 | 1.20–2.34 | | |
|             |      | GG | 71 (21.0) | 54 (12.2) | 2.62 | 1.68–4.08 | 6.08*10^{-4}/0.02 | |
| SERPINA5    | rs6112 | CC | 120 (34.9) | 227 (50.2) | 1.00 | Referent | | |
|             |      | CT | 182 (52.9) | 196 (43.4) | 1.72 | 1.25–2.36 | | |
|             |      | TT | 42 (12.2) | 29 (6.4) | 2.72 | 1.56–4.75 | 2.23*10^{-3}/0.04 | |
| SERPINA5    | rs6108 | TT | 107 (31.3) | 187 (41.6) | 1.00 | Referent | | |
|             |      | AT | 173 (50.6) | 218 (48.4) | 1.34 | 0.96–1.86 | | |
|             |      | AA | 62 (18.1) | 45 (10.0) | 2.54 | 1.56–4.12 | 0.00028/0.37 | |
| SERPINA5    | rs10139508 | AA | 118 (34.4) | 208 (46.0) | 1.00 | Referent | | |
|             |      | AG | 183 (53.4) | 203 (44.9) | 1.74 | 1.26–2.39 | | |
|             |      | GG | 42 (12.2) | 41 (9.1) | 1.90 | 1.12–3.20 | 0.00075/0.50 | |
| MASP1       | rs850316 | GG | 79 (23.0) | 157 (34.7) | 1.00 | Referent | | |
|             |      | AG | 180 (52.3) | 215 (47.6) | 1.67 | 1.17–2.38 | | |
| HEMGN       | rs10984462 | TT | 216 (63.0) | 246 (54.4) | 1.00 | Referent | | |
|             |      | GT | 114 (33.2) | 166 (36.7) | 0.72 | 0.52–0.99 | | |
|             |      | GG | 13 (3.8) | 40 (8.8) | 0.35 | 0.18–0.68 | 0.0087/0.50 | |
| TICAM1      | rs2292151 | GG | 182 (52.9) | 283 (63.0) | 1.00 | Referent | | |
|             |      | AG | 133 (38.7) | 145 (32.3) | 1.50 | 1.09–2.07 | | |
|             |      | AA | 29 (8.4) | 21 (4.7) | 2.34 | 1.25–4.38 | 0.00088/0.50 | |

*SNP-based linear $P_{SNP-trend}$ is calculated based on the three-level genotype (0, 1, and 2) in logistic regression models adjusted for sex, attained age, and year of birth.

**False discovery rate (FDR) corrected linear $P_{SNP-trend}$.

doi:10.1371/journal.pone.0057243.t002

### Table 3. Significance levels (P values) for an association with papillary thyroid cancer for the selected gene regions with uncorrected $P_{Region} < 0.01$.

| Gene Region | Chromosome Band | Number of SNPs | $P_{Region}$ | $P_{Region-FDR}$ |
|-------------|-----------------|----------------|--------------|------------------|
| SERPINA5    | 14q32.1         | 26             | 0.0003/0.069 | |
| HEMGN       | 9q22.33         | 5              | 0.0016/0.183 | |
| TICAM1      | 19p13.3         | 15             | 0.0066/0.426 | |
| FCGR2A      | 1q23            | 8              | 0.0074/0.426 | |

*Gene region-based P values ($P_{Region}$) calculated using the adaptive rank truncated product method.

**False discovery rate (FDR) corrected $P_{Region}$.

doi:10.1371/journal.pone.0057243.t003
Table 4. Pathway-based significance levels ($P$ values) for each immunity pathway analyzed, with and without accounting for overlapping genes between pathways.

| Pathway                                           | With overlap | Without overlap |
|---------------------------------------------------|--------------|-----------------|
|                                                   | $P_{Pathway}$ | Number of Genes | $P_{Pathway}$ | Number of Genes |
| Adhesion-extravasation-migration                   | 0.82         | 33              | 0.80          | 30              |
| Arachidonic acid metabolism/eicosanoid signaling   | 0.56         | 20              | 0.56          | 20              |
| Complement and coagulation cascade                 | 0.02         | 25              | 0.02          | 25              |
| Cytokine signaling                                 | 0.90         | 75              | 0.85          | 63              |
| Innate pathogen detection and antimicrobials       | 0.15         | 46              | 0.16          | 41              |
| Leukocyte signaling                                | 0.23         | 20              | 0.20          | 14              |
| TNF/NF-κB signaling                                | 0.05         | 7               | 0.04          | 13              |
| Other                                             | 0.07         | 7               | 0.08          | 7               |
| Overall                                           | 0.22         | 235             | 0.18          | 212             |

*Some gene regions were allocated to more than one pathway, creating overlap. To calculate $P$ values without overlap in multiple pathway allocations, these specific gene regions were dropped from their respective pathways.

Pathway-based $P$ values ($P_{Pathway}$) were calculated using the adaptive rank truncated product method.

doi:10.1371/journal.pone.0057243.t004

power are essential to establish causal variants in the SERPINA5 region.

Supporting Information

Table S1 Gene regions and their allocation to the respective pathways: U. S. Radiologic Technologists Study and University of Texas M. D. Anderson Cancer Center Study of papillary thyroid cancer.

Table S2 $P$ values of linear trend for 3,985 SNPs in immune related genes: U. S. Radiologic Technologists Study and University of Texas M. D. Anderson Cancer Center Study of papillary thyroid cancer.

Table S3 Gene region-based $P$ values for an association with thyroid cancer: U. S. Radiologic Technologists Study and University of Texas M. D. Anderson Cancer Center Study of papillary thyroid cancer.

Acknowledgments

We are grateful to the radiologic technologists who participated in the U. S. Radiologic Technologists Study; Jerry Reid of the American Registry of Radiologic Technologists for continued support of this study; Diane Kampa and Allison Iwan of the University of Minnesota for data collection and study coordination; Liliana Mugartegui for patient recruitment, data collection, and study coordination at the University of Texas M. D. Anderson Cancer Center; Laura Bowen of Information Management Systems for biomedical computing statistical support. It is with great sadness that we report the death of our colleague Dr. Elaine Ron during the project. Her astute insights and collegial support are greatly appreciated.

Author Contributions

Conceived and designed the experiments: AJS EMS MAT SJC. Performed the experiments: AH MY. Analyzed the data: AVB GN RMP LX CZ WW. Contributed reagents/materials/analysis tools: RMP AH MY WW. Contributed to the writing of the manuscript: AJS EMS MAT SJC. Performed microarray analyses: AVB GN. Contributed reagents/materials/analysis tools: AVB GN. Written the draft: AJS EMS MAT SJC.

References

1. Sipos JA, Mazzaferrri EL (2010) Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 22: 395–404.
2. Davies L, Welch HG (2006) Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA 299: 2164–2167.
3. Ennewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, et al. (2009) Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980–2005. Cancer Epidemiol Biomarkers Prev 18: 784–791.
4. Rahul R, Zhang L, Kebebew E (2010) Thyroid cancer gender disparity. Future Oncol 6: 1711–1719.
5. Ron E, Lahun BH, Shore RE, Mahushki K, Modan B, et al. (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141: 259–277.
6. Simmott B, Ron E, Schneider AB (2010) Exposing the thyroid to radiation: a review of its current extent, risks, and implications. Endocr Rev 31: 756–773.
7. Xu O, Li G, Wei Q, El-Naggar A, Sturgis EM (2012) Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer 118: 1228–1235.
8. Brindel P, Doyon F, Bourgain C, Rachedi F, Boissin JL, et al. (2010) The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 17: 3449–3461.
9. Guarino V, Castellone MD, Avilla E, Molillo RM (2010) Thyroid cancer and inflammation. Mol Cell Endocrinol 321: 94–102.
10. Takahashi M, Sano KM, Roganovitch T, Kawaguchi T, Dousa VM, et al. (2010) The FOXE1 locus is a major genetic determinant for radiation-related thyroid carcinoma in Chernobyl. Hum Mol Genet 19: 2516–2523.
11. Landa I, Ruiz-Llorente S, Montero-Conde C, Inglanda-Perez I, Schiavi F, et al. (2009) The variant rs1067277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet 5: e1000637.
12. Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, et al. (2010) The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 17: 3449–3461.
13. Guarino V, Castellone MD, Avilla E, Molillo RM (2010) Thyroid cancer and inflammation. Mol Cell Endocrinol 321: 94–102.
14. Mous SF, Blaser MJ (2005) Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol 2: 90–97; quiz 91 p following 113.
15. Weng MY, Huang YT, Liu MF, Lu TH (2012) Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjögren’s syndrome in Taiwan. Ann Rheum Dis 71: 524–527.
16. Prasad ML, Huang Y, Pellegata NS, de la Chapelle A, Kloos RT (2004) Prader-Willi syndrome predisposes to thyroid cancer. Hum Mol Genet 13: 2509–2514.
17. Muzza M, DeGirolomonti D, Colombo C, Perrino M, Ravan R, et al. (2010) The tight relationship between papillary thyroid cancer, autoimmunity and
inflammation: clinical and molecular studies. Clin Endocrinol (Oxf) 72: 702–708.

18. Kivity S, Ehrenfeld M (2010) Can we explain the higher prevalence of autoimmune disease in women? Expert Rev Clin Immunol 6: 691–694.

19. Vandebroek K (2012) Cytokine gene polymorphisms and human autoimmune disease in the era of genome-wide association studies. J Interferon Cytokine Res 32: 139–151.

20. Cooper JD, Simmonds MJ, Walker NM, Burden O, Brand OJ, et al. (2012) Seven newly identified loci for autoimmune thyroid disease. Hum Mol Genet.

21. Sigurdson AJ, Doody MM, Rao RS, Freedman DM, Alexander BH, et al. (2003) Cancer incidence in the US radiologic technologists health study, 1983–1998. Cancer 97: 3080–3089.

22. Ho T, Li G, Lu J, Zhao C, Wei Q, et al. (2009) Association of XRCC1 polymorphisms and risk of differentiated thyroid carcinoma: a case-control analysis. Thyroid 19: 129–135.

23. Li M, Bhatti P, Alexander B, Pinuela M, Doody M, et al. (2007) Papillary thyroid cancer and polymorphic variants in TSHR- and RET-related genes: A nested case-control study within a cohort of US radiologic technologists. Cancer Epidemiology Biomarkers and Prevention 16: 174–177.

24. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, et al. (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74: 106–120.

25. Tarone RE (1990) A modified Bonferroni method for discrete data. Biometrics 46: 545–522.

26. Loza MJ, McCall CE, Li L, Isaacs WB, Xu J, et al. (2007) Assembly of inflammation-related genes for pathway-focused genetic analysis. PLoS One 2: e1035.

27. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate - a Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society Series B-Methodological 57: 289–300.

28. Yu K, Li Q, Bergen AW, Pfeiffer RM, Rosenberg PS, et al. (2009) Pathway analysis by adaptive combination of P-values. Genet Epidemiol 33: 700–709.

29. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263–265.

30. Meijers JC, Herwaldt H (2011) Protein C inhibitor. Semin Thromb Hemost 37: 349–354.

31. Malmstrom E, Moeplin M, Malmsten M, Johansson L, Norby-Teglund A, et al. (2009) Protein C inhibitor-a novel antimicrobial agent. PLoS Pathog 5: e1000688.

32. Suzuki K (2008) The multi-functional serpin, protein C inhibitor beyond thrombosis and hemoatasis. J Thromb Haemost 6: 2017–2026.

33. Espana F, Navarro S, Medina P, Zorio E, Estelles A (2007) The role of protein C inhibitor in human reproduction. Semin Thromb Hemost 33: 41–45.

34. Han MH, Hwang SI, Roy DB, Lundgren DH, Price JV, et al. (2008) Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451: 1076–1081.

35. Bijmans IT, Smits KM, de Graeff P, Wismans GB, van der Zee AG, et al. (2011) Loss of SerpinA1 protein expression is associated with advanced-stage serous ovarian tumors. Mod Pathol 24: 463–470.

36. Vierlinger K, Mansfeld MH, Koperek O, Nohammer C, Kaserrer K, et al. (2011) Identification of SERPINA1 as single marker for papillary thyroid carcinoma through microarray meta analysis and quantification of its discriminatory power in independent validation. BMC Med Genomics 4: 30.

37. Stein L, Rothschild J, Luce J, Cowell JK, Thomas G, et al. (2010) Copy number and gene expression alterations in radiation-induced papillary thyroid carcinoma from chernobyl pediatric patients. Thyroid 20: 475–487.

38. Bungum M, Giwercman A, Bungum L, Humaidan P, Rastkiani H, et al. (2010) Polymorphisms in the protein C inhibitor gene in in vitro fertilization failure. Fertil Steril 93: 277–279.

39. Boergmann S, Eades G, Urban S, Sitter T, Fricke H (2001) A linkage disequilibrium between genes at the serine protease inhibitor gene cluster on chromosome 14p32.1 is associated with Wegener’s granulomatosis. Clin Immunol 98: 244–248.

40. Castanet M, Polak M (2010) Spectrum of Human Foxe1/TTF2 Mutations. Horm Res Paediatr 73: 423–429.

41. Denny JC, Crawford DC, Ritchie MD, Bienias SJ, Batford MA, et al. (2011) Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. Am J Hum Genet 89: 529–542.

42. Eriksson N, Tung JY, Kirke AK, Hindus DA, Francke U, et al. (2012) Novel associations for hypothyroidism include known autoimmune risk loci. PLoS One 7: e44142.